Dissociated amyloid-β antibody levels as a serum biomarker for the progression of Alzheimer’s disease: A population-based study
- 31 January 2010
- journal article
- Published by Elsevier BV in Experimental Gerontology
- Vol. 45 (1), 47-52
- https://doi.org/10.1016/j.exger.2009.10.003
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Vascular oxidative stress in Alzheimer diseaseJournal of the Neurological Sciences, 2007
- Plasma amyloid-β concentrations in Alzheimer's disease: an alternative hypothesisThe Lancet Neurology, 2006
- Neuropathology of Alzheimer disease: pathognomonic but not pathogenicActa Neuropathologica, 2006
- Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type.Journal of Neuropathology and Experimental Neurology, 2004
- Neuropathological diagnostic criteria for Alzheimer's diseaseNeuropathology, 2004
- Cerebrospinal fluid protein biomarkers for Alzheimer’s diseaseNeuroRX, 2004
- Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer DiseaseArchives of Neurology, 1999
- Formal education as an effect modifier of the relationship between Mini-Mental State Examination score and IADLs disability in the older populationAging Clinical and Experimental Research, 1997
- Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human PlasmaJournal of Biological Chemistry, 1996
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984